Halozyme Therapeutics HALO · NASDAQ
$103.63 -15.72% (-$19.33)
Summary
87 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 27 USD is left as net profit.
- Earnings per share grew by 21% a year over the last 3 years.
- It earns 23 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $1.03B against $305.6M.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.2 USD for 1 USD of yearly profit. Over the last five years it was 22.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 39% a year over 5 years. Over the last 3 years it grew by 28% a year. For the next fiscal year analysts expect revenue to grow by 35%. Earnings per share grew by 21% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 21 USD
- Research and development 6.3 USD
- Sales and administration 16 USD
- Taxes and other 30 USD
- Net profit 27 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 27 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 9
- Sell 1
Today's price within the analysts' price targets
The average target of $110 is 6.1% above today's price. 63% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Royalty 54%
- Product 23%
- Collaborative Agreements 9.4%
- Bulk rHuPH20 8.2%
- Sales-based milestone 4.3%
- Other 1.1%
By region
- SWITZERLAND 73%
- UNITED STATES 27%
Royalty brings in 54% of revenue.
Segments in detail